Advertisement
Advertisement
U.S. markets open in 8 hours 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.84-0.20 (-0.74%)
At close: 04:00PM EDT
26.84 0.00 (0.00%)
After hours: 04:32PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close27.04
Open26.98
Bid0.00 x 800
Ask0.00 x 900
Day's Range25.85 - 27.65
52 Week Range22.67 - 41.73
Volume1,228,510
Avg. Volume1,193,808
Market Cap1.747B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-4.86
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GBT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Global Blood Therapeutics, Inc.
    QURE: What does Argus have to say about QURE?UNIQURE NV has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

    New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an

  • Simply Wall St.

    Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week

    If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

  • Motley Fool

    Why Global Blood Therapeutics Stock Was Sickly Today

    For the quarter, Global Blood Therapeutics' sales hit nearly $55.2 million, representing quite an encouraging improvement over the year-ago quarter's $39 million. Although the revenue figure didn't quite reach the $56.1 million analysts were collectively estimating, Global Blood Therapeutics beat on the bottom line. Global Blood Therapeutics also launched the drug for patients aged 4 to 11.

Advertisement
Advertisement